Crossmark

Velopalatine and Bilateral Vocal Cord Paralysis Associated with Atezolizumab Treatment: A Severe and Previously Undocumented Side Effect in Cancer Immunotherapy

Crossref DOI link: https://doi.org/10.1007/s12070-024-04709-5

Published Online: 2024-04-20

Published Print: 2024-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lorente-Piera, Joan

Zufiaurre, Natalia Díaz

Fernández-González, Secundino

Alcalde, Juan
License Information

Text and Data Mining valid from 2024-04-20

Version of Record valid from 2024-04-20
More Information

Article History

Received: 4 March 2024

Accepted: 15 April 2024

First Online: 20 April 2024

Declarations

:

: Only approval from the respective local ethics committee for the involved institutions was required for the researchers, as this observational study did not involve novel, invasive, or exceptional interventions. This study was designed and conducted in accordance with the ethical guidelines of the 1975 Declaration of Helsinki.

: The authors declare there are no financial conflicts of interest to disclose.

: The authors declare they have no competing interests.

Document is current

Any future updates will be listed below